Abstract
The ELITE-II, BEST and CHAMP Trials were reported for the first time at the American Heart Association in November 1999. These trials provide valuable new information to guide clinical practice in the management of heart failure and of myocardial infarction, although none mandate a major change from current clinical practice. The IMPRESS trial of the vasopeptidase inhibitor, omapatrilat, indicated a promising new treatment for the management of heart failure.
MeSH terms
-
Adrenergic beta-Antagonists / therapeutic use
-
Angiotensin-Converting Enzyme Inhibitors / therapeutic use
-
Antihypertensive Agents / therapeutic use
-
Captopril / therapeutic use
-
Exercise Tolerance
-
Heart Failure / drug therapy*
-
Humans
-
Losartan / therapeutic use
-
Pyridines / therapeutic use
-
Randomized Controlled Trials as Topic
-
Thiazepines / therapeutic use
Substances
-
Adrenergic beta-Antagonists
-
Angiotensin-Converting Enzyme Inhibitors
-
Antihypertensive Agents
-
Pyridines
-
Thiazepines
-
omapatrilat
-
Captopril
-
Losartan